KDC-MN-379 – Kodiac biolabs

Plain-language summaryIntrigue 70 / 100

Lisdexamfetamine is a clever prodrug of d-amphetamine, sold as Vyvanse since 2007. The trick is that the amphetamine molecule is chemically tied to the amino acid lysine, which makes the conjugate biologically inactive. Once swallowed, enzymes inside red blood cells slowly cleave the lysine off, releasing free d-amphetamine over several hours. The result is a smoother, flatter blood curve than immediate-release amphetamine and a lower abuse ceiling, since crushing or injecting it does not speed up the enzymatic conversion. Approved for ADHD and binge eating disorder. Schedule II despite the abuse-deterrent design. The standard reference for prodrug-style stimulant engineering. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

48/100

Clever abuse-deterrent prodrug chemistry that has aged into a mature, well-documented reference standard

Look, lisdexamfetamine is a genuinely clever piece of prodrug chemistry, and thats worth acknowledging upfront. The lysine conjugation approach solved a real problem in 2007: how do you deliver d-amphetamine with flat pharmacokinetics and substantially reduced abuse liability? The answer was to conjugate the active amine to L-lysine and rely on red blood cell cytosolic peptidase activity for slow, sustained cleavage. The consequence is that parenteral routes lose their pharmacokinetic advantage entirely, since the enzymatic step still has to happen. For a formulation innovation, that mechanism is elegant in a way most reformulation work isnt.

But here’s the thing: that story is nearly twenty years old now. Vyvanse launched in 2007, the prodrug chemistry was characterized and published quickly, and the field has spent the time since validating what investigators already knew. The evidence base is obviously solid. Multiple phase 3 trials across ADHD and binge eating disorder, regulatory approval in over a dozen jurisdictions, long-term safety data. We’re not disputing that lisdexamfetamine works or that the pharmacokinetic profile compares favorably to immediate-release mixed amphetamine salts in certain contexts.

What we don’t see is a research frontier. The mechanism is mature. Clinical pharmacology is fully characterized. If you’re studying dopamine transporter pharmacology at the bench, you’re using d-amphetamine itself as the tool compound, not the prodrug. If the project is specifically about prodrug cleavage kinetics or RBC enzymatic activity, that’s a narrow niche. The abuse-deterrent prodrug literature that lisdexamfetamine helped seed has been written, largely. The canonical papers are out there and the field has moved on to other problems.

We think the most credible ongoing research angle is lisdexamfetamine as a reference compound in pharmacokinetic modeling or abuse-potential comparison paradigms, and there’s some continuing interest in the BED indication where the mechanistic framing around impulse control circuitry and dopamine is at least somewhat distinct from classic ADHD pharmacotherapy. The BED evidence base is still thinner than the ADHD data, and some groups are probing executive function and emotional dysregulation endpoints in that population. That’s interesting at the margins.

Honestly, the bench value here is limited unless the program is specifically about Schedule II stimulant comparison, dopaminergic pharmacokinetics, or prodrug delivery mechanisms. The Schedule II designation adds real regulatory overhead, and the scientific upside doesn’t clear the bar to make allocation a priority. Strong evidence and translational signal from an approved drug pull the score up meaningfully; near-zero novelty and modest mechanism interest bring it back toward the middle. A serious investigator would treat this as a reference standard, not a frontier target.

Novelty: 25
Mechanism promise: 32
In-category differentiation: 52
Evidence quality: 76
Translational signal: 72
Research bench value: 40

Rationale Schedule II cap (65) does not bind; raw score of 48 reflects a well-evidenced approved drug with strong translational signal but near-zero frontier novelty and limited bench probe value. The lysine-conjugation prodrug story is intellectually elegant but two decades settled, pulling novelty and mechanism scores into the lower range and keeping the overall well below the schedule cap.

Prodrug d-amphetamine (lysine conjugate)

L-lysine-d-amphetamine conjugate; a prodrug providing slow conversion to active d-amphetamine, with reduced abuse potential.

Abstract

Lisdexamfetamine ((2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide; CAS 608137-32-2; molecular formula C15H25N3O; molecular weight 263.38) is a prodrug of d-amphetamine in which the amphetamine amino group is conjugated with L-lysine via a peptide bond. Approved by the FDA in 2007 (Vyvanse). Mechanism: the prodrug is biologically inactive; following oral absorption, red blood cell cytosolic enzymes hydrolyze the lysine-amphetamine bond, releasing free d-amphetamine over several hours. The slow, sustained release produces a flatter plasma curve than IR amphetamine and reduces the rate of dopamine increase that drives abuse liability. The lysine conjugation also means parenteral routes (IV, snorted) do not produce a faster onset, since the cleavage requires enzymatic activity. Approved indications: ADHD and binge eating disorder. Plasma half-life of the released d-amphetamine is approximately 11 hours. Schedule II. Used as the canonical abuse-deterrent stimulant prodrug.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-379Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-379

Lisdexamfetamine

Abstract

Read the full monograph